At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 8, 2026 at 07:00 ET
Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, showing disease-modifying activity comparable or superior to approved therapies in multiple lupus models. The Phase 1 healthy volunteer trial is ongoing with data expected in 2H26. This is a positive pipeline update for a mid-stage biotech, but preclinical data alone does not guarantee clinical success.
- KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models.
- Data presented at EULAR (June 3-6, 2026) and FOCIS (June 9-12, 2026) meetings.
- KT-579 Phase 1 healthy volunteer trial is ongoing; data expected in second half of 2026.
- KT-579 is a first-in-class oral degrader of IRF5, a genetically validated transcription factor.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access